GSK3787PPARβ/δ antagonist,novel and irreversible CAS# 188591-46-0 |
- 3-Deazaneplanocin,DZNep
Catalog No.:BCC1129
CAS No.:102052-95-9
- GSK126
Catalog No.:BCC1604
CAS No.:1346574-57-9
- EPZ005687
Catalog No.:BCC2219
CAS No.:1396772-26-1
- EPZ-6438
Catalog No.:BCC3634
CAS No.:1403254-99-8
- EI1
Catalog No.:BCC4044
CAS No.:1418308-27-6
- UNC1999
Catalog No.:BCC4552
CAS No.:1431612-23-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 188591-46-0 | SDF | Download SDF |
| PubChem ID | 2800647 | Appearance | Powder |
| Formula | C15H12ClF3N2O3S | M.Wt | 392.78 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO | ||
| Chemical Name | 4-chloro-N-[2-[5-(trifluoromethyl)pyridin-2-yl]sulfonylethyl]benzamide | ||
| SMILES | C1=CC(=CC=C1C(=O)NCCS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)Cl | ||
| Standard InChIKey | JFUIMTGOQCQTPF-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C15H12ClF3N2O3S/c16-12-4-1-10(2-5-12)14(22)20-7-8-25(23,24)13-6-3-11(9-21-13)15(17,18)19/h1-6,9H,7-8H2,(H,20,22) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent and selective peroxisome proliferator-activated receptor δ (PPARδ) antagonist (pIC50 = 6.6). Displays no measurable affinity for PPARα or PPARγ in vitro (pIC50< 5). |
GSK3787 Dilution Calculator
GSK3787 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.546 mL | 12.7298 mL | 25.4595 mL | 50.9191 mL | 63.6489 mL |
| 5 mM | 0.5092 mL | 2.546 mL | 5.0919 mL | 10.1838 mL | 12.7298 mL |
| 10 mM | 0.2546 mL | 1.273 mL | 2.546 mL | 5.0919 mL | 6.3649 mL |
| 50 mM | 0.0509 mL | 0.2546 mL | 0.5092 mL | 1.0184 mL | 1.273 mL |
| 100 mM | 0.0255 mL | 0.1273 mL | 0.2546 mL | 0.5092 mL | 0.6365 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
GSK3787 is a novel and irreversible antagonist of the peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) that covalently binds to a cysteine residue in the ligand-binding domain of PPAR- β/δ. Although it responses to ligand activation to modulate the association of both PPAR-β/δ and PPAR-γ coregulator peptides, GSK3787 exhibits considerably higher antagonism of PPAR-β/δ than that of PPAR-γ. Results of recent studies have shown that oral administration of GSK3787 results in the antagonism of GW0742-induced overexpression of Angptl4 and Adrp mRNA in wild-type mouse colon, which is correlated with reduced promoter occupancy of PPAR-β/δ on the Angptl4 and Adrp genes.
Reference
Palkar PS, Borland MG, Naruhn S, Ferry CH, Lee C, Sk UH, Sharma AK, Amin S, Murray IA, Anderson CR, Perdew GH, Gonzalez FJ, Müller R, Peters JM. Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787. Mol Pharmacol. 2010;78(3):419-430
- Cl-4AS-1
Catalog No.:BCC7780
CAS No.:188589-66-4
- TFM-4AS-1
Catalog No.:BCC6069
CAS No.:188589-61-9
- SBI-0206965
Catalog No.:BCC3984
CAS No.:1884220-36-3
- Scandoside
Catalog No.:BCN3449
CAS No.:18842-99-4
- Paederosidic acid
Catalog No.:BCN3438
CAS No.:18842-98-3
- MAFP
Catalog No.:BCC7059
CAS No.:188404-10-6
- Pellitorine
Catalog No.:BCN4043
CAS No.:18836-52-7
- Isodomoic acid G
Catalog No.:BCN1839
CAS No.:188346-81-8
- Massonianoside B
Catalog No.:BCN1164
CAS No.:188300-19-8
- Californidine
Catalog No.:BCC8137
CAS No.:18830-99-4
- 8alpha-(2-Methylacryloyloxy)hirsutinolide
Catalog No.:BCN7109
CAS No.:188293-70-1
- (±)-Propionylcarnitine chloride
Catalog No.:BCC6719
CAS No.:18828-58-5
- 3-hydroxymorindone
Catalog No.:BCN3126
CAS No.:80368-74-7
- 4,5-Di-O-caffeoylquinic acid methyl ester
Catalog No.:BCN6492
CAS No.:188742-80-5
- N-Acetylcaprolactam
Catalog No.:BCC9081
CAS No.:1888-91-1
- SC 560
Catalog No.:BCC7111
CAS No.:188817-13-2
- 8-Glucosyl-5,7-dihydroxy-2-(1-methylpropyl)chromone
Catalog No.:BCN7505
CAS No.:188818-27-1
- Streptozotocin
Catalog No.:BCN3834
CAS No.:18883-66-4
- HX 531
Catalog No.:BCC6082
CAS No.:188844-34-0
- HX 630
Catalog No.:BCC6083
CAS No.:188844-52-2
- DMA
Catalog No.:BCC1532
CAS No.:188860-26-6
- Hydroxytanshinone IIA
Catalog No.:BCN2497
CAS No.:18887-18-8
- Methyl tanshinonate
Catalog No.:BCN2553
CAS No.:18887-19-9
- Junipediol B 8-O-glucoside
Catalog No.:BCN4022
CAS No.:188894-19-1
Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787.[Pubmed:20516370]
Mol Pharmacol. 2010 Sep;78(3):419-30.
The availability of high-affinity agonists for peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) has led to significant advances in our understanding of the functional role of PPARbeta/delta. In this study, a new PPARbeta/delta antagonist, 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), was characterized using in vivo and in vitro models. Orally administered GSK3787 caused antagonism of 4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethylsulfanyl]-2-m ethyl-phenoxy}-acetic acid (GW0742)-induced up-regulation of Angptl4 and Adrp mRNA expression in wild-type mouse colon but not in Pparbeta/delta-null mouse colon. Chromatin immunoprecipitation (ChIP) analysis indicates that this correlated with reduced promoter occupancy of PPARbeta/delta on the Angptl4 and Adrp genes. Reporter assays demonstrated antagonism of PPARbeta/delta activity and weak antagonism and agonism of PPARgamma activity but no effect on PPARalpha activity. Time-resolved fluorescence resonance energy transfer assays confirmed the ability of GSK3787 to modulate the association of both PPARbeta/delta and PPARgamma coregulator peptides in response to ligand activation, consistent with reporter assays. In vivo and in vitro analysis indicates that the efficacy of GSK3787 to modulate PPARgamma activity is markedly lower than the efficacy of GSK3787 to act as a PPARbeta/delta antagonist. GSK3787 antagonized GW0742-induced expression of Angptl4 in mouse fibroblasts, mouse keratinocytes, and human cancer cell lines. Cell proliferation was unchanged in response to either GW0742 or GSK3787 in human cancer cell lines. Results from these studies demonstrate that GSK3787 can antagonize PPARbeta/delta in vivo, thus providing a new strategy to delineate the functional role of a receptor with great potential as a therapeutic target for the treatment and prevention of disease.
Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist.[Pubmed:20128594]
J Med Chem. 2010 Feb 25;53(4):1857-61.
4-Chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide 3 (GSK3787) was identified as a potent and selective ligand for PPARdelta with good pharmacokinetic properties. A detailed binding study using mass spectral analysis confirmed covalent binding to Cys249 within the PPARdelta binding pocket. Gene expression studies showed that pyridylsulfone 3 antagonized the transcriptional activity of PPARdelta and inhibited basal CPT1a gene transcription. Compound 3 is a PPARdelta antagonist with utility as a tool to elucidate PPARdelta cell biology and pharmacology.
